Trimodality management of malignant pleural mesothelioma.

OBJECTIVE: We reviewed our experience with trimodality management of malignant pleural mesothelioma (MPM).

METHODS: From September 1998 to August 2000, 32 consecutive patients with histological diagnosis of MPM underwent trimodality therapy, including mesothelioma surgery followed by adjuvant chemotherapy and radiation therapy. Surgery consisted of pleurectomy/decortication (P/D) or pleural-pericardial-pneumonectomy and diaphragm (PPPD). Pre-operative staging according to the Brigham Staging System was accomplished using computed tomography (CT) and magnetic resonance imaging (MRI); patients with evident extrapleural spread were excluded.

RESULTS: Our series included 21 men and 11 women with a median age of 53.5 years (range 40-69). Histologically, there were 26 epithelial, four mixed and two sarcomatous MPM. Post-surgical staging was as follows: six patients were at Stage 1; of these, two received a P/D and four a PPPD. Ten patients were at Stage 2 and all received a PPPD; 16 patients were at Stage 3 (under-staged pre-operatively): of these, nine patients presented extrapleural lymph node metastases (N2) and all received a PPPD, seven patients presented with chest wall or mediastinal invasion (T4) with macroscopic residual tumour, and all received a de-bulking P/D. We observed major complications in ten patients: six bleeding, two respiratory insufficiency and two nerve paralysis. There were two perioperative deaths (6.25% mortality). Twenty-seven patients out of 30 surviving surgery had a follow-up greater than 6 months; 21 patients out of 27 are alive with a median follow-up of 12.5 months.

CONCLUSIONS: (1) Trimodality therapy is feasible in selected patients with malignant pleural mesothelioma and has an acceptable operative mortality rate. (2) Our current pre-operative staging based on CT/MRI looks rather inaccurate and needs to be improved. (3) The high rate of post-surgical N2 patients or with diffusion to the inferior surface of the diaphragm may suggest the use of routine mediastinoscopy and laparoscopy for a more appropriate patient selection.

Source

PMID: 11251277 [PubMed - indexed for MEDLINE]
Click here to order or save article

If you have any questions regarding treatment options or your legal rights, please contact us.

Free Mesothelioma Information Packet

Enter your information to receive a comprehensive mesothelioma packet free of charge at your doorstep within 24 hours.

Yes   No

Mesothelioma Mesothelioma Treatment Asbestos Cancer Asbestos Exposure Mesothelioma News Veterans & Mesothelioma Mesothelioma Attorney FREE Case Evaluation Top Mesothelioma Doctors

Richard L. Kradin, M.D.
Dr. Richard Kradin is an Associate Pathologist at Massachusetts General Hospital in the Immunopathology Unit where he performs tissue culture and immunocytochemistry.

Borys Mychalczak, M.D.
Dr. Borys Mychalczak is Chief of Radiation Oncology at the Memorial Sloan-Kettering regional care facility in Sleepy Hollow, New York.

David Rice, M.D.
Dr. David Rice is an Associate Professor and Assistant Surgeon at The University of Texas M.D. Anderson Cancer Center where he serves as the director of the Minimally Invasive Surgery and Mesothelioma programs.

This website is certified by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information:
verify here.